Synthetica, a pioneering developer of live bacteria drugs based in Shenzhen, has announced the successful completion of its first round of financing, with the specific amount remaining undisclosed. The round was led by Boehringer Ingelheim Venture Fund and Temasek, with participation from Lenovo Capital and Incubator Group, Fosun Health, and other investors. The capital raised will be directed towards advancing Synthetica’s pipeline of oncolytic bacteria drugs into clinical studies.
Established in 2023, Synthetica specializes in the development of anti-tumor live bacteria drugs that are designed to be safe, efficient, broad-spectrum, targeted, and non-invasive. The company leverages an in-depth understanding of gene pathways and precise regulation of gene and payload expression, utilizing advanced quantitative synthetic biology techniques to create its innovative therapeutics.- Flcube.com
